ClinicalTrials.gg
CompletedNCT01726023RECLAIM3Updated Sep 6, 2017Results posted

Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections

A Phase 3 interventional study of Ceftazidime-avibactam and metronidazole in Complicated Intra-abdominal Infection, sponsored by Pfizer. Completed at 30 sites in 3 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2017-09-06.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
486
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Intraabdominal Infections by Pfizer — none open to participants now, none under way, none of them phase 3. Intraabdominal Infections · Pfizer.

Enrollment
2nd of 14
486 · median 144
Started
2013
with 2 others
Phase 3
5 of 19
none open now
Registered
13th of 19
by date

Among the 19 studies in Intraabdominal Infections by Pfizer, this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2013, is one of 5 in phase 3, and was the 13th registered.

Intraabdominal Infections

129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.

Browse Intraabdominal Infections studies →

Open to participants now

None of the 19 studies in Intraabdominal Infections by Pfizer is open now. The open studies under Intraabdominal Infections, anywhere →

Who these studies take

Of the 10 Intraabdominal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Intraabdominal Infections by Pfizer as a file.
02

Study summary

The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.

Read the detailed description

A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults

03

Conditions studied

  • Complicated Intra-abdominal Infection

Keywords

  • Ceftazidime-avibactam,
  • Metronidazole,
  • Meropenem,
  • Anti-Bacterial Agents,
  • Anti-Infective Agents,
  • Therapeutic Uses,
  • Pharmacologic Actions,
  • Physiological Effects of Drugs
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must be 18 to 90 years of age, inclusive,
  • Female patients can participate if they are surgically sterilized or for at least 1 year or her sexual partner has had a vasectomy
  • Female of has had normal menstrual periods for 3 months and negative serum pregnancy test and agree to practice highly effective methods of during treatment and for at least 7 days after last dose
  • Intraoperative/postoperative enrollment with visual confirmation (presence of pus within the abdominal cavity) of an intra-abdominal infection associated with peritonitis
  • Confirmation of infection by surgical intervention within 24 hours of entry: evidence of systemic inflammatory indicators; physical findings consistent with intra-abdominal infection; supportive radiologic imaging findings of intra-abdominal infections

Exclusion criteria

Exclusion Criteria:

  • Patient is diagnosed with traumatic bowel perforation undergoing surgery within 12 hours; perforation of gastroduodenal ulcers undergoing surgery within 24 hours. Other intra-abdominal processes in which primary etiology is not likely to be infectious
  • Patient has abdominal wall abscess or bowel obstruction without perforation or ischemic bowel without perforation
  • Patients whose surgery will include staged abdominal repair, or "open abdomen" technique, or marsupialization
  • Patient has suspected intra-abdominal infections due to fungus, parasites, virus or tuberculosis
  • Patient is considered unlikely to survive the 6- to 8-week study period or has a rapidly progressive or terminal illness, including septic shock that is associated with a high risk of mortality
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
486 participants (actual)

Study arms

  • Experimental
    Ceftazidime-Avibactam plus metronidazole

    Drug: Ceftazidime-avibactam · Drug: metronidazole

  • Active comparator
    Meropenem

    Drug: Meropenem

Interventions

  • DrugCeftazidime-avibactam

    Ceftazidime-Avibactam powder for concentrate for solution for infusion 2000 mg/500 mg

  • Metronidazole 500mg/100ml solution for infusion

  • Meropenem powder for solution for infusion 1000mg

06

What researchers measure

Primary outcomes

  1. The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Clinically Evaluable (CE) Analysis Set.

    The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

    Time frame: At the test of cure visit (Day 28 to35)

Secondary outcomes

  1. The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.

    The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

    Time frame: At the end of treatment (EOT) (within 24 hours after last IV dose)

  2. The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.

    The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

    Time frame: At the test of cure (TOC) (Day 28 to 35)

  3. The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.

    The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

    Time frame: At the late follow up (LFU) (Day 42 to 49)

  4. The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

    The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

    Time frame: At the end of treatment (EOT) (within 24 hours after last IV dose)

  5. The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

    The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

    Time frame: At the test of cure (TOC) (Day 28 to 35)

  6. The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

    The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

    Time frame: At the late follow up (LFU) (Day 42 to 49)

  7. The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

    The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

    Time frame: At the end of treatment (EOT) (within 24 hours after last IV dose)

  8. The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

    The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

    Time frame: At the test of cure (TOC) (Day 28 to 35)

  9. The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

    The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

    Time frame: At the late follow up (LFU) (Day 42 to 49)

  10. The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Clinically Evaluable (CE) Analysis Set.

    The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

    Time frame: At the end of treatment (EOT) (within 24 hours after last IV dose)

  11. The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Clinically Evaluable (CE) Analysis Set.

    The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

    Time frame: At late follow up (LFU) visits (Day 42 to 49)

  12. The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.

    Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".

    Time frame: At the end of treatment (EOT) (within 24 hours after last IV dose)

  13. The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.

    Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".

    Time frame: At the test of cure (TOC) (Day 28 to 35)

  14. The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.

    Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".

    Time frame: At the late follow up (LFU) (Day 42 to 49)

  15. The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

    Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".

    Time frame: At the end of treatment (EOT) (within 24 hours after last IV dose)

  16. The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

    Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".

    Time frame: At the test of cure (TOC) (Day 28 to 35)

  17. The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

    Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".

    Time frame: At the late follow up (LFU) (Day 42 to 49)

  18. The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

    Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".

    Time frame: At the end of treatment (EOT) (within 24 hours after last IV dose)

  19. The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

    Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".

    Time frame: At the test of cure (TOC) (Day 28 to 35)

  20. The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

    Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".

    Time frame: At the late follow up (LFU) (Day 42 to 49)

  21. The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

    The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

    Time frame: At the end of treatment (EOT) (within 24 hours after last IV dose)

  22. The Proportion of Favorable Per-pathogen Microbiological Response in the Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

    The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

    Time frame: At the test of cure (TOC) (Day 28 to 35)

  23. The Proportion of Favorable Per-pathogen Microbiological Response in the Microbiological Response at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

    The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

    Time frame: At the late follow up (LFU) (Day 42 to 49)

  24. The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.

    The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

    Time frame: At the end of treatment (EOT) (within 24 hours after last IV dose)

  25. The Proportion of Favorable Per-pathogen Microbiological Response at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.

    The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

    Time frame: At the test of cure (TOC) (Day 28 to 35)

  26. The Proportion of Favorable Per-pathogen Microbiological Response at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.

    The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

    Time frame: At the late follow up (LFU) (Day 42 to 49)

  27. The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

    The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

    Time frame: At the end of treatment (EOT) (within 24 hours after last IV dose)

  28. The Proportion of Favorable Per-pathogen Microbiological Response at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable(ME) Analysis Set.

    The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

    Time frame: At the test of cure (TOC) (Day 28 to 35)

  29. The Proportion of Favorable Per-pathogen Microbiological Response at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

    The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

    Time frame: At the late follow up (LFU) (Day 42 to 49)

  30. The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

    The microbiological responses as per the protocoled criteria: responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence).

    Time frame: At the test of cure (TOC) (Day 28 to 35)

  31. The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Microbiologically Evaluable (ME) Analysis Set.

    The microbiological responses as per the protocoled criteria: responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence).

    Time frame: At the test of cure (TOC) (Day 28 to 35)

  32. The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Extended Microbiologically Evaluable (ME) Analysis Set.

    The microbiological responses as per the protocoled criteria: responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence).

    Time frame: At the test of cure (TOC) (Day 28 to 35)

  33. The Time to First Defervescence in the Clinically Evaluable (CE) Analysis Set for Patients Who Have Fever at Study Entry.

    Time to first defervescence was calculated for patients with a fever (\>38ºC) at baseline. Defervescence (≤37.8ºC) was defined as the absence of fever based on the highest temperature recorded on each study day. Time to first defervescence while on IV study therapy in the CE analysis set at TOC for patients who had fever at study entry is defined as time (in days) from the first dose of IV study therapy to first absence of fever.

    Time frame: while on study therapy (from Day 1 to Day 14)

  34. The Time to First Defervescence in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set for Patients Who Have Fever at Study Entry.

    Time to first defervescence was calculated for patients with a fever (\>38ºC) at baseline. Defervescence (≤37.8ºC) was defined as the absence of fever based on the highest temperature recorded on each study day. Time to first defervescence while on IV study therapy in the CE analysis set at TOC for patients who had fever at study entry is defined as time (in days) from the first dose of IV study therapy to first absence of fever.

    Time frame: while on study therapy (from Day 1 to Day 14)

  35. Safety and Tolerability by Incidence and Severity of Adverse Events and Serious Adverse Events and Mortality.

    Adverse event data were collected from the screening/consent visit until the late follow-up visit (i.e. Day -1/0 to Day 42).

    Time frame: study duration (from screening to Day 49 LFU visit)

  36. Safety and Tolerability by Incidence: Extent of Exposure.

    Duration of exposure is calculated as the difference between the last study therapy date and the first study therapy date converted to days plus 1 day. Actual calculated duration could be shorter or longer than a full day.

    Time frame: study duration (from screening to Day 49 LFU visit)

  37. Safety and Tolerability: Clinical Laboratory Evaluation Hematology.

    Potentially clinically significant (PCS) post Baseline hematology values up to LFU (Safety analysis set)

    Time frame: study duration (from screening to Day 49 LFU visit)

  38. Safety and Tolerability: Clinical Laboratory Evaluation Clinical Chemistry.

    Potentially clinically significant (PCS) post Baseline clinical chemistry values up to LFU (Safety analysis set)

    Time frame: study duration (from screening to Day 49 LFU visit)

  39. Safety and Tolerability:ECG , QTcB and QTcF Intervals

    Shifts in ECG interpretation and changes in QT, QTcB, and QTcF intervals , from baseline to post baseline.

    Time frame: EOT visit/any observation on treatment

  40. Plasma Concentrations for Ceftazidime and Avibactam

    Blood samples were taken from all patients on Day 3 for the pharmacokinetic evaluation of ceftazidime and avibactam plasma concentrations

    Time frame: At Day 3: Anytime within 15 minutes prior to or after stopping study drug, anytime between 30 and 90 minutes after stopping study drug, anytime between 300 minutes and 360 minutes after stopping study drug.

07

Results

Posted Apr 14, 2016

Participant flow

Overall, 486 patients were enrolled from 43 centers in 3 countries in this study. The first patient was enrolled on 14 January 2013 and the last patient last visit was on 14 March 2015.

Participant flow — Overall Study
MilestoneCeftazidime-Avibactam Plus MetronidazoleMeropenem
Started219222
Completed190196
Not completed2926
Withdrew: Death11
Withdrew: Lost to follow-up510
Withdrew: Other eligibility criteria77
Withdrew: Withdrawal by subject168

Outcome measures

PrimaryThe Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Clinically Evaluable (CE) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

Time frame:
At the test of cure visit (Day 28 to35)
Reported as:
Number · Number of patients
The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Clinically Evaluable (CE) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Clinical cure166173
Clinical failure1111
Statistical analysis
  • Ceftazidime-Avibactam Plus Metronidazole vs Meropenem · % Risk Difference (RD) · p = <0.001 (P-value for 1-sided test at test of cure (TOC) with a -12.5% non-inferiority margin, i.e. H0: diff ≤ -12.5%.) · Risk difference (rd): -0.20 · 95% CI -5.53 to 4.97units for RD are %
SecondaryThe Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

Time frame:
At the end of treatment (EOT) (within 24 hours after last IV dose)
Reported as:
Number · Number of patients
The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Clinical cure103113
Clinical failure35
SecondaryThe Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

Time frame:
At the test of cure (TOC) (Day 28 to 35)
Reported as:
Number · Number of patients
The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Clinical cure92107
Clinical failure76
SecondaryThe Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

Time frame:
At the late follow up (LFU) (Day 42 to 49)
Reported as:
Number · Number of patients
The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Clinical cure89100
Clinical failure76
SecondaryThe Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

Time frame:
At the end of treatment (EOT) (within 24 hours after last IV dose)
Reported as:
Number · Number of patients
The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Clinical cure104120
Clinical failure35
SecondaryThe Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

Time frame:
At the test of cure (TOC) (Day 28 to 35)
Reported as:
Number · Number of patients
The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Clinical cure93113
Clinical failure76
SecondaryThe Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

Time frame:
At the late follow up (LFU) (Day 42 to 49)
Reported as:
Number · Number of patients
The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Clinical cure90106
Clinical failure76
SecondaryThe Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

Time frame:
At the end of treatment (EOT) (within 24 hours after last IV dose)
Reported as:
Number · Number of patients
The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Clinical cure126140
Clinical failure67
Indeterminate115
SecondaryThe Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

Time frame:
At the test of cure (TOC) (Day 28 to 35)
Reported as:
Number · Number of patients
The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Clinical cure119135
Clinical failure109
Indeterminate148
SecondaryThe Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

Time frame:
At the late follow up (LFU) (Day 42 to 49)
Reported as:
Number · Number of patients
The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Clinical cure116132
Clinical failure109
Indeterminate1711
SecondaryThe Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Clinically Evaluable (CE) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

Time frame:
At the end of treatment (EOT) (within 24 hours after last IV dose)
Reported as:
Number · Number of patients
The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Clinically Evaluable (CE) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Clinical cure183187
Clinical failure79
SecondaryThe Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Clinically Evaluable (CE) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

Time frame:
At late follow up (LFU) visits (Day 42 to 49)
Reported as:
Number · Number of patients
The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Clinically Evaluable (CE) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Clinical cure157168
Clinical failure1111
SecondaryThe Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.

Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".

Time frame:
At the end of treatment (EOT) (within 24 hours after last IV dose)
Reported as:
Number · Number of patients
The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Favorable103113
Unfavorable35
SecondaryThe Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.

Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".

Time frame:
At the test of cure (TOC) (Day 28 to 35)
Reported as:
Number · Number of patients
The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Favorable92107
Unfavorable76
SecondaryThe Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.

Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".

Time frame:
At the late follow up (LFU) (Day 42 to 49)
Reported as:
Number · Number of patients
The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Favorable89100
Unfavorable76
SecondaryThe Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".

Time frame:
At the end of treatment (EOT) (within 24 hours after last IV dose)
Reported as:
Number · Number of patients
The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Favorable104120
Unfavorable35
SecondaryThe Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".

Time frame:
At the test of cure (TOC) (Day 28 to 35)
Reported as:
Number · Number of patients
The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Favorable93113
Unfavorable76
SecondaryThe Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".

Time frame:
At the late follow up (LFU) (Day 42 to 49)
Reported as:
Number · Number of patients
The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Favorable90106
Unfavorable76
SecondaryThe Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".

Time frame:
At the end of treatment (EOT) (within 24 hours after last IV dose)
Reported as:
Number · Number of patients
The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Favorable126140
Unfavorable67
Indeterminate115
SecondaryThe Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".

Time frame:
At the test of cure (TOC) (Day 28 to 35)
Reported as:
Number · Number of patients
The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Favorable119135
Unfavorable109
Indeterminate148
SecondaryThe Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".

Time frame:
At the late follow up (LFU) (Day 42 to 49)
Reported as:
Number · Number of patients
The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Favorable116132
Unfavorable109
Indeterminate1711
SecondaryThe Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

Time frame:
At the end of treatment (EOT) (within 24 hours after last IV dose)
Reported as:
Number · Participants with favorable responses
The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
Participants with favorable responsesCeftazidime-Avibactam Plus MetronidazoleMeropenem
Escherichia coli (n=84, 89)7786
Klebsiella oxytoca (n=5, 5)55
Klebsiella pneumoniae (n=28,35)2232
Pseudomonas aeruginosa (n=17, 20)1517
Streptococcus anginosus grou (n=8, 7)76
Streptococcus mitis group (n=6, 5)65
Enterococcus faecalis (n=6, 6)55
Enterococcus faecium (n=4, 7)45
SecondaryThe Proportion of Favorable Per-pathogen Microbiological Response in the Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

Time frame:
At the test of cure (TOC) (Day 28 to 35)
Reported as:
Number · Participants with favorable responses
The Proportion of Favorable Per-pathogen Microbiological Response in the Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
Participants with favorable responsesCeftazidime-Avibactam Plus MetronidazoleMeropenem
Escherichia coli (n=84, 89)7084
Klebsiella oxytoca (n=5, 5)55
Klebsiella pneumoniae (n=28,35)2331
Pseudomonas aeruginosa (n=17, 20)1417
Streptococcus anginosus group (n=8, 7)75
Streptococcus mitis group (n=6, 5)65
Enterococcus faecalis (n=6, 6)64
Enterococcus faecium (n=4, 7)45
SecondaryThe Proportion of Favorable Per-pathogen Microbiological Response in the Microbiological Response at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

Time frame:
At the late follow up (LFU) (Day 42 to 49)
Reported as:
Number · Participants with favorable responses
The Proportion of Favorable Per-pathogen Microbiological Response in the Microbiological Response at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
Participants with favorable responsesCeftazidime-Avibactam Plus MetronidazoleMeropenem
Escherichia coli (n=84, 89)7082
Klebsiella pneumoniae (n=28, 35)2231
Pseudomonas aeruginosa (n=17, 20)1417
Klebsiella oxytoca (n=5, 5)45
Enterococcus faecalis (n=6, 6)44
Enterococcus faecium (n=4, 7)35
Streptococcus anginosus group (n=8, 7)75
Streptococcus mitis group (n=6, 5)65
SecondaryThe Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

Time frame:
At the end of treatment (EOT) (within 24 hours after last IV dose)
Reported as:
Number · Participants with favorable responses
The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.
Participants with favorable responsesCeftazidime-Avibactam Plus MetronidazoleMeropenem
Escherichia coli (n=69, 77)6875
Klebsiella oxytoca (n=5, 5)55
Klebsiella pneumoniae (n=22, 29)2128
Pseudomonas aeruginosa (n=14, 16)1414
SecondaryThe Proportion of Favorable Per-pathogen Microbiological Response at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

Time frame:
At the test of cure (TOC) (Day 28 to 35)
Reported as:
Number · Participants with favorable responses
The Proportion of Favorable Per-pathogen Microbiological Response at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.
Participants with favorable responsesCeftazidime-Avibactam Plus MetronidazoleMeropenem
Escherichia coli (n=69, 77)6474
Klebsiella oxytoca (n=5, 5)55
Klebsiella pneumoniae (n=22, 29)2128
Pseudomonas aeruginosa (n=14, 16)1314
SecondaryThe Proportion of Favorable Per-pathogen Microbiological Response at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

Time frame:
At the late follow up (LFU) (Day 42 to 49)
Reported as:
Number · Participants with favorable responses
The Proportion of Favorable Per-pathogen Microbiological Response at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.
Participants with favorable responsesCeftazidime-Avibactam Plus MetronidazoleMeropenem
Escherichia coli (n=69, 77)6372
Klebsiella oxytoca (n=5, 5)45
Klebsiella pneumoniae (n=22, 29)2127
Pseudomonas aeruginosa (n=14, 16)1314
SecondaryThe Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

Time frame:
At the end of treatment (EOT) (within 24 hours after last IV dose)
Reported as:
Number · Participants with favorable responses
The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
Participants with favorable responsesCeftazidime-Avibactam Plus MetronidazoleMeropenem
Escherichia coli (n=70, 80)6978
Klebsiella oxytoca (n=5, 5)55
Klebsiella pneumoniae (n=22, 30)2129
Pseudomonas aeruginosa (n=14, 18)1416
SecondaryThe Proportion of Favorable Per-pathogen Microbiological Response at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable(ME) Analysis Set.

The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

Time frame:
At the test of cure (TOC) (Day 28 to 35)
Reported as:
Number · Participants with favorable responses
The Proportion of Favorable Per-pathogen Microbiological Response at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable(ME) Analysis Set.
Participants with favorable responsesCeftazidime-Avibactam Plus MetronidazoleMeropenem
Escherichia coli (n=70, 80)6577
Klebsiella oxytoca (n=5, 5)55
Klebsiella pneumoniae (n=22, 30)2129
Pseudomonas aeruginosa (n=14, 18)1316
SecondaryThe Proportion of Favorable Per-pathogen Microbiological Response at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

Time frame:
At the late follow up (LFU) (Day 42 to 49)
Reported as:
Number · Participants with favorable responses
The Proportion of Favorable Per-pathogen Microbiological Response at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
Participants with favorable responsesCeftazidime-Avibactam Plus MetronidazoleMeropenem
Escherichia coli (n=70, 80)6475
Klebsiella oxytoca (n=5, 5)45
Klebsiella pneumoniae (n=22, 30)2128
Pseudomonas aeruginosa (n=14, 18)1316
SecondaryThe Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

The microbiological responses as per the protocoled criteria: responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence).

Time frame:
At the test of cure (TOC) (Day 28 to 35)
Reported as:
Number · Number of patients
The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Favorable2427
Unfavorable11
Indeterminate41
SecondaryThe Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Microbiologically Evaluable (ME) Analysis Set.

The microbiological responses as per the protocoled criteria: responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence).

Time frame:
At the test of cure (TOC) (Day 28 to 35)
Reported as:
Number · Number of patients
The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Microbiologically Evaluable (ME) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Favorable2223
Unfavorable11
SecondaryThe Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Extended Microbiologically Evaluable (ME) Analysis Set.

The microbiological responses as per the protocoled criteria: responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence).

Time frame:
At the test of cure (TOC) (Day 28 to 35)
Reported as:
Number · Number of patients
The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Extended Microbiologically Evaluable (ME) Analysis Set.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Favorable2225
Unfavorable11
SecondaryThe Time to First Defervescence in the Clinically Evaluable (CE) Analysis Set for Patients Who Have Fever at Study Entry.

Time to first defervescence was calculated for patients with a fever (\>38ºC) at baseline. Defervescence (≤37.8ºC) was defined as the absence of fever based on the highest temperature recorded on each study day. Time to first defervescence while on IV study therapy in the CE analysis set at TOC for patients who had fever at study entry is defined as time (in days) from the first dose of IV study therapy to first absence of fever.

Time frame:
while on study therapy (from Day 1 to Day 14)
Reported as:
Median · Days
The Time to First Defervescence in the Clinically Evaluable (CE) Analysis Set for Patients Who Have Fever at Study Entry.
DaysCeftazidime-Avibactam Plus MetronidazoleMeropenem
The Time to First Defervescence in the Clinically Evaluable (CE) Analysis Set for Patients Who Have Fever at Study Entry.1 (1 to 5)1.5 (1 to 4)
Statistical analysis
  • Ceftazidime-Avibactam Plus Metronidazole vs Meropenem · Log Rank · p = 0.773 · Difference in median time (days): 0.5
SecondaryThe Time to First Defervescence in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set for Patients Who Have Fever at Study Entry.

Time to first defervescence was calculated for patients with a fever (\>38ºC) at baseline. Defervescence (≤37.8ºC) was defined as the absence of fever based on the highest temperature recorded on each study day. Time to first defervescence while on IV study therapy in the CE analysis set at TOC for patients who had fever at study entry is defined as time (in days) from the first dose of IV study therapy to first absence of fever.

Time frame:
while on study therapy (from Day 1 to Day 14)
Reported as:
Median · Days
The Time to First Defervescence in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set for Patients Who Have Fever at Study Entry.
DaysCeftazidime-Avibactam Plus MetronidazoleMeropenem
The Time to First Defervescence in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set for Patients Who Have Fever at Study Entry.1 (1 to 5)2 (1 to 4)
Statistical analysis
  • Ceftazidime-Avibactam Plus Metronidazole vs Meropenem · Log Rank · p = 0.598 · Difference in median time (days): 1
SecondarySafety and Tolerability by Incidence and Severity of Adverse Events and Serious Adverse Events and Mortality.

Adverse event data were collected from the screening/consent visit until the late follow-up visit (i.e. Day -1/0 to Day 42).

Time frame:
study duration (from screening to Day 49 LFU visit)
Reported as:
Number · Number of patients
Safety and Tolerability by Incidence and Severity of Adverse Events and Serious Adverse Events and Mortality.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Any AE8283
Any SAE911
Any AE leading to discontinuation of IP73
Any AE of severe intensity55
Total number of deaths21
Deaths due to disease progression20
Any AE with outcome=death01
SecondarySafety and Tolerability by Incidence: Extent of Exposure.

Duration of exposure is calculated as the difference between the last study therapy date and the first study therapy date converted to days plus 1 day. Actual calculated duration could be shorter or longer than a full day.

Time frame:
study duration (from screening to Day 49 LFU visit)
Reported as:
Number · Number of patients
Safety and Tolerability by Incidence: Extent of Exposure.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
1 - 2 days105
3 - 4 days65
5 -10 days175181
11 - 14 days2426
>14 days00
SecondarySafety and Tolerability: Clinical Laboratory Evaluation Hematology.

Potentially clinically significant (PCS) post Baseline hematology values up to LFU (Safety analysis set)

Time frame:
study duration (from screening to Day 49 LFU visit)
Reported as:
Number · Number of patients
Safety and Tolerability: Clinical Laboratory Evaluation Hematology.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Platelet count: PCS (Low)11
Platelet count: PCS (High)54
Red blood cell count: PCS (Low)713
Red blood cell count: PCS (High)00
White blood cell: PCS (Low)11
White blood cell: PCS (High)45
Hemoglobin: PCS (Low)714
Hemoglobin: PCS (High)00
Lymphocytes: PCS (Low)11
Lymphocytes: PCS (High)01
Neutrophils: PCS (Low)42
Neutrophils: PCS (High)98
Eosinophils: PCS (High)00
Monocytes: PCS (High)00
Basophils: PCS (High)00
Direct Coombs test:- at Baseline, + post-Baseline152
Hematocrit (ratio): PCS (Low)58
Hematocrit (ratio): PCS (High)00
SecondarySafety and Tolerability: Clinical Laboratory Evaluation Clinical Chemistry.

Potentially clinically significant (PCS) post Baseline clinical chemistry values up to LFU (Safety analysis set)

Time frame:
study duration (from screening to Day 49 LFU visit)
Reported as:
Number · Number of patients
Safety and Tolerability: Clinical Laboratory Evaluation Clinical Chemistry.
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Alanine aminotransferase (μkat/L): PCS (High)38
Alkaline phosphatase (μkat/L): PCS (Low)00
Alkaline phosphatase (μkat/L): PCS (High)23
Aspartate aminotransferase (μkat/L): PCS (High)44
Bicarbonate (mmol/L) PCS (Low)10
Bicarbonate (mmol/L): PCS (High)00
Creatinine (μmol/L): PCS (High)01
Glucose (non-fasting) (mmol/L): PCS (Low)00
Glucose (non-fasting) (mmol/L): PCS (High)11
Gamma-glutamyl transferase (μkat/L):PCS (High)24
Inorganic phosphorus (mmol/L): PCS (Low)37
Inorganic phosphorus (mmol/L): PCS (High)00
Potassium (mmol/L): PCS (Low)95
Potassium (mmol/L): PCS (High)31
Total bilirubin (μmol/L): PCS (High)01
Direct bilirubin (μmol/L): PCS (High)11
SecondarySafety and Tolerability:ECG , QTcB and QTcF Intervals

Shifts in ECG interpretation and changes in QT, QTcB, and QTcF intervals , from baseline to post baseline.

Time frame:
EOT visit/any observation on treatment
Reported as:
Number · Number of patients
Safety and Tolerability:ECG , QTcB and QTcF Intervals
Number of patientsCeftazidime-Avibactam Plus MetronidazoleMeropenem
Normal to Abnormal: EOT1714
Normal to Abnormal: Anytime up to EOT3430
Reaching a value in QT: ≥450 (ms)910
Reaching a value in QT: ≥480 (ms)21
Reaching a value in QT: ≥500 (ms)00
QT: ≥500 and increase from Baseline ≥60(ms)00
Increase in QT: ≥30 (ms)115114
Increase in QT: ≥60 (ms)5044
Decrease in QT: ≥30 (ms)2424
Decrease in QT: ≥60 (ms)124
Reaching a value in QTcB: ≥450(ms)5763
Reaching a value in QTcB: ≥480(ms)138
Reaching a value in QTcB: ≥500 (ms)42
QTcB: ≥500 and increase from Baseline ≥60(ms)21
Increase in QTcB: ≥30 (ms)2127
Increase in QTcB: ≥60 (ms)21
Decrease in QTcB: ≥30 (ms)4226
Decrease in QTcB: ≥60 (ms)64
Reaching a value in QTcF: ≥450 (ms)1918
Reaching a value in QTcF: ≥480 (ms)40
Reaching a value in QTcF: ≥500 (ms)10
QTcF: ≥500 and increase from Baseline ≥60 (ms)00
Increase in QTcF: ≥30 (ms)4241
Increase in QTcF: ≥60 (ms)43
Decrease QTcF: ≥30 (ms)2119
Decrease QTcF: ≥60 (ms)71
SecondaryPlasma Concentrations for Ceftazidime and Avibactam

Blood samples were taken from all patients on Day 3 for the pharmacokinetic evaluation of ceftazidime and avibactam plasma concentrations

Time frame:
At Day 3: Anytime within 15 minutes prior to or after stopping study drug, anytime between 30 and 90 minutes after stopping study drug, anytime between 300 minutes and 360 minutes after stopping study drug.
Reported as:
Geometric mean · ng/mL
Plasma Concentrations for Ceftazidime and Avibactam
ng/mLCeftazidime(1)Avibactam(1)Ceftazidime(2)Avibactam(2)Ceftazidime(3)Avibactam(3)
Plasma Concentrations for Ceftazidime and Avibactam60300.4 (1390 to 1880000)10126.9 (197 to 435000)46473.9 (2080 to 210000)7289.3 (229 to 36300)9555.0 (1740 to 222000)1207.2 (227 to 36300)

Adverse events

Collected over Adverse event data were collected from the screening/consent visit until the late follow-up visit (i.e. Day -1/0 to Day 42). FOR SAE's - only those reported by 2 or more patients in either group are shown in this summary.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CAZ-AVI Plus Metronidazole—9/215 (4.2%)44/215 (20.5%)
Meropenem—11/217 (5.1%)47/217 (21.7%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventCAZ-AVI Plus MetronidazoleMeropenem
AnaemiaBlood and lymphatic system disorders1/2150/217
Arteriosclerosis coronary arteryCardiac disorders1/2150/217
Abdominal pain lowerGastrointestinal disorders1/2150/217
GastritisGastrointestinal disorders1/2150/217
Cholangitis acuteHepatobiliary disorders1/2150/217
Hepatic function abnormalHepatobiliary disorders1/2150/217
Abdominal infectionInfections and infestations1/2150/217
Postoperative wound infectionInfections and infestations1/2151/217
MetastasisNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2150/217
Acute kidney injuryRenal and urinary disorders1/2151/217
Most frequent other events
Most frequent other events
EventCAZ-AVI Plus MetronidazoleMeropenem
NauseaGastrointestinal disorders18/2154/217
DiarrhoeaGastrointestinal disorders13/21516/217
PyrexiaGeneral disorders9/21512/217
CoughRespiratory, thoracic and mediastinal disorders3/2158/217
Hepatic function abnormalHepatobiliary disorders0/2156/217
Productive coughRespiratory, thoracic and mediastinal disorders5/2156/217
ConstipationGastrointestinal disorders5/2153/217
VomitingGastrointestinal disorders5/2154/217
HeadacheNervous system disorders3/2155/217

Baseline characteristics

Baseline analysis population is MITT ; Randomized patients who received any amount of study therapy, excluding patients who received both study therapies. 9 patients were randomized but not treated, and one patient received doses of both treatments.

Age, Continuous
Age, Continuous(Years)Ceftazidime-Avibactam Plus MetronidazoleMeropenemTotal
Mean48.5 ± 16.8348.5 ± 17.4348.5 ± 17.11
Age, Customized
Age, Customized(Participants)Ceftazidime-Avibactam Plus MetronidazoleMeropenemTotal
18-45 Years8996185
46-64 Years8572157
65-74 Years283058
75-90 Years121931
Sex: Female, Male
Sex: Female, Male(Participants)Ceftazidime-Avibactam Plus MetronidazoleMeropenemTotal
Female7364137
Male141153294
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ceftazidime-Avibactam Plus MetronidazoleMeropenemTotal
Asian214217431
08

Study locations

30 sites
  • Research Site
    Baotou, China
  • Research Site
    Beijing, China
  • Research Site
    Changsha, China
  • Research Site
    Chengdu, China
  • Research Site
    Chongqing, China
  • Research Site
    Fuzhou, China
  • Research Site
    Guangzhou, China
  • Research Site
    Guilin, China
  • Research Site
    Haikou, China
  • Research Site
    Hebei, China
  • Research Site
    Jiangyin, China
  • Research Site
    Liaocheng, China
  • Research Site
    Nan Chang, China
  • Research Site
    Shanghai, China
  • Research Site
    Tianjin, China
  • Research Site
    Urumqi, China
  • Research Site
    Wenzhou, China
  • Research Site
    Wuxi, China
  • Research Site
    Xi'an, China
  • Research Site
    Ansan-si, Korea, Republic of
  • Research Site
    Anyang-si, Korea, Republic of
  • Research Site
    Busan, Korea, Republic of
  • Research Site
    Cheongju-si, Korea, Republic of
  • Research Site
    Daejeon, Korea, Republic of
  • Research Site
    Gwangju, Korea, Republic of
  • Research Site
    Jinju-si, Korea, Republic of
  • Research Site
    Seoul, Korea, Republic of
  • Research Site
    Wonju-si, Korea, Republic of
  • Research Site
    Hanoi, Vietnam
  • Research Site
    Hochiminh, Vietnam
09

References and documents

Publications

  • Cheng K, Newell P, Chow JW, Broadhurst H, Wilson D, Yates K, Wardman A. Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme. Drug Saf. 2020 Aug;43(8):751-766. doi: 10.1007/s40264-020-00934-3. PubMed 32602065 ↗
  • Li J, Lovern M, Green ML, Chiu J, Zhou D, Comisar C, Xiong Y, Hing J, MacPherson M, Wright JG, Riccobene T, Carrothers TJ, Das S. Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups. Clin Transl Sci. 2019 Mar;12(2):151-163. doi: 10.1111/cts.12585. Epub 2018 Sep 28. PubMed 30221827 ↗
  • Nichols WW, Stone GG, Newell P, Broadhurst H, Wardman A, MacPherson M, Yates K, Riccobene T, Critchley IA, Das S. Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2018 Oct 24;62(11):e02590-17. doi: 10.1128/AAC.02590-17. Print 2018 Nov. PubMed 30061279 ↗
  • Stone GG, Newell P, Gasink LB, Broadhurst H, Wardman A, Yates K, Chen Z, Song J, Chow JW. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme. J Antimicrob Chemother. 2018 Sep 1;73(9):2519-2523. doi: 10.1093/jac/dky204. PubMed 29912399 ↗
  • Qin X, Tran BG, Kim MJ, Wang L, Nguyen DA, Chen Q, Song J, Laud PJ, Stone GG, Chow JW. A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia. Int J Antimicrob Agents. 2017 May;49(5):579-588. doi: 10.1016/j.ijantimicag.2017.01.010. Epub 2017 Mar 29. PubMed 28363526 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2012
First posted
Nov 14, 2012
Start
Jan 2013
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results first posted
Apr 14, 2016
Last update
Sep 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01726023
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 14, 2012
Start date
Jan 2013
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Apr 14, 2016
Last update
Sep 6, 2017

Study contacts

Paul A Newell, MBBS, MRCP
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metronidazole

Start the discussion